Febuxostat for hyperuricemia in patients with advanced chronic kidney disease

Drug Target Insights

Volumn 2014, Issue 8, 2014, Pages 39-43

  Akimoto, Tetsu ^a,b   Morishita, Yoshiyuki ^a,b   Ito, Chiharu ^a,b   Iimura, Osamu ^b   Tsunematsu, Sadao ^b   Watanabe, Yuko ^a   Kusano, Eiji ^a   Nagata, Daisuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Green Town Clinic ^*  (Japan)

Author keywords

Chronic kidney disease; Febuxostat; Hemodialysis; Oxidative stress; Uric acid

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; FEBUXOSTAT; URIC ACID;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERURICEMIA; LOW DRUG DOSE; MALE; OXIDATIVE STRESS; SEX; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 84921768757     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.s16524     Document Type: Article

References (28)

1. Gafo AL, Saag KG. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evid. 2009;4:25-36.
2. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-2461.
3. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment efects of febuxostat. J Clin Rheumatol. 2011;17(1):7-13.
4. Fujimori S, Ooyama K, Ooyama H, Moromizato H. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1035-1038.
5. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646-1650.
6. Hosoya T, Ono I. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol. 2011;17(4 suppl 2):S27-S34.
7. Horikoshi R, Akimoto T, Inoue M, Morishita Y, Kusano E. Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment. Clin Exp Nephrol. 2013;17(1):149-150.
8. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508-2516.
9. Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427(2):266-272.
10. Morishita Y, Watanabe M, Hirahara I, Akimoto T, Muto S, Kusano E. Level of 8-OHdG in drained dialysate appears to be a marker of peritoneal damage in peritoneal dialysis. Int J Nephrol Renovasc Dis. 2012;5:9-14.
11. Yamanaka H. Japanese society of gout and nucleic acid metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucle-osides Nucleotides Nucleic Acids. 2011;30(12):1018-1029.
12. El-Zawawy H, Mandell BF. Managing gout: how is it diferent in patients with chronic kidney disease? Cleve Clin J Med. 2010;77(12):919-928.
13. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Terapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-1324.
14. Smith EU, Díaz-Torné C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24(6):811-827.
15. Ifudu O, Tan CC, Dulin AL, Delano BG, Friedman EA. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis. 1994;23(3):347-351.
16. Ohno I, Ichida K, Okabe H, et al. Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Intern Med. 2005;44(7):706-709.
17. Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011;6(10):2470-2477.
18. George J, Struthers A. Te role of urate and xanthine oxidase in vascular oxida-tive stress: future directions. Ter Clin Risk Manag. 2009;5:799-803.
19. Malik UZ, Hundley NJ, Romero G, et al. Febuxostat inhibition of endothelial-bound XO: implication for targeting vascular ROS production. Free Radic Biol Med. 2011;51(1):179-184.
20. Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013; 77(8):2043-2049.
21. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009;22(6):636-643.
22. Grifths HR, Dias IH, Willetts RS, Devitt A. Redox regulation of protein damage in plasma. Redox Biol. 2014;2:430-435.
23. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin Dial. 2009;22(4):405-408.
24. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol. 2004;142(2):231-255.
25. Jalalzadeh M, Nurcheshmeh Z, Mohammadi R, Mousavinasab N, Ghadiani MH. The effect of allopurinol on lowering blood pressure in hemodi-alysis patients with hyperuricemia. J Res Med Sci. 2012;17(11):1039-1046.
26. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(6): 435-442.
27. Argilés A, Mourad G, Mion C. Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis. N Engl J Med. 1998; 339(19):1364-1370.
28. Murea M. Advanced kidney failure and hyperuricemia. Adv Chronic Kidney Dis. 2012;19(6):419-424.